Gemini PharmChem Mannheim GmbH develops, manufactures and sells specialist products for healthcare and the pharmaceutical and chemical industries and provides consulting and other services. The company owns research, production and storage buildings on a chemical site acquired in 2013; production facilities for cytostatics have been operational since the end of 2018. GMP certificates have been granted since May 2020; further certificates for Nelarabine, Valrubicin and Idarubicin followed in 2021, an FDA inspection was successfully completed in January 2022 and a GMP re-inspection was passed in February 2023. Worldwide procurement and product distribution are handled exclusively by the sole shareholder Synbias AG, and more than 50% of 2024 revenue was generated with Epirubicin; capacity utilization still lags behind expectations.
Die Entwicklung, Herstellung und der Vertrieb von Spezialprodukten auf den Gebieten Gesundheitswesen, der pharmazeutischen und chemischen Industrie sowie die Erbringung von Beratungs- und sonstigen Dienstleistungen. Die Gesellschaft kann alle Geschäfte betreiben und Handlungen vornehmen, die geeignet sind, dem Gesellschaftszweck unmittelbar oder mittelbar zu dienen. Dazu zählt auch der Erwerb, die Verwaltung und die Vermietung von beweglichen und unbeweglichen Vermögensgegenständen, die insbesondere der Betätigung auf den Gebieten Gesundheitswesen und pharmazeutische und chemische Industrie dienen.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Mannheim Local Court, HRB 718005 (as of 18 August 2026)
Source: German Commercial Register (Handelsregister) Mannheim Local Court, HRB 718005 (as of 18 August 2026)
Sign in to download data
Source: German Commercial Register (Handelsregister) Mannheim Local Court, HRB 718005 (as of 18 August 2026)
Sign in to view detailed salary and cost trends.
